内毒素耐受导致单核细胞代谢灵活性丧失：理解脓毒症引起免疫麻痹的模型？
Loss of monocyte metabolic plasticity in endotoxin tolerance: A model for understanding sepsis-induced immune paralysis?
机构信息
Department of Surgery, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, 37614, USA.
Center of Excellence in Inflammation, Infectious Disease and Immunity, East Tennessee State University, Johnson City, Tennessee, 37614, USA.
出版信息
J Leukoc Biol. 2019 Jul;106(1):7-9. doi: 10.1002/JLB.4CE0319-100R. Epub 2019 May 14.
Abstract
Discussion on implications of the immune paralysis that occurs in many sepsis patients.
摘要
探讨许多脓毒症患者中出现的免疫麻痹的影响。
相似文献
1
Loss of monocyte metabolic plasticity in endotoxin tolerance: A model for understanding sepsis-induced immune paralysis?内毒素耐受导致单核细胞代谢灵活性丧失：理解脓毒症引起免疫麻痹的模型？
J Leukoc Biol. 2019 Jul;106(1):7-9. doi: 10.1002/JLB.4CE0319-100R. Epub 2019 May 14.
2
Frontline Science: Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst.前沿科学：内毒素诱导的免疫耐受与单核细胞代谢灵活性的丧失和氧化爆发的减少有关。
J Leukoc Biol. 2019 Jul;106(1):11-25. doi: 10.1002/JLB.5HI0119-018R. Epub 2019 Jun 6.
3
Impaired endotoxin tolerance induction in patients with familial Mediterranean fever.家族性地中海热患者内毒素耐受诱导受损。
Pathobiology. 2006;73(1):26-39. doi: 10.1159/000093089.
4
Dexamethasone, colchicine and iodine-lithium-alpha-dextrin act differentially on the oxidative burst and endotoxin tolerance induction in vitro in patients with Behçet's disease.地塞米松、秋水仙碱和碘-锂-α-糊精对贝赫切特病患者体外氧化爆发和内毒素耐受诱导的作用各不相同。
Int Immunopharmacol. 2006 Mar;6(3):396-407. doi: 10.1016/j.intimp.2005.09.003. Epub 2005 Oct 7.
5
Influence of surgery and endotoxin-induced sepsis combined on natural killer cell activity, oxidative burst of granulocytes and antigen presentation capability of monocytes.手术与内毒素诱导的脓毒症联合作用对自然杀伤细胞活性、粒细胞氧化爆发及单核细胞抗原呈递能力的影响
Acta Anaesthesiol Scand. 2002 Apr;46(4):405-10. doi: 10.1034/j.1399-6576.2002.460413.x.
6
NFκB2/p100 is a key factor for endotoxin tolerance in human monocytes: a demonstration using primary human monocytes from patients with sepsis.NFκB2/p100是人类单核细胞内毒素耐受的关键因素：一项对脓毒症患者原代人单核细胞的研究证明
J Immunol. 2014 Oct 15;193(8):4195-202. doi: 10.4049/jimmunol.1400721. Epub 2014 Sep 15.
7
Endotoxin tolerance: new mechanisms, molecules and clinical significance.内毒素耐受：新机制、分子及临床意义。
Trends Immunol. 2009 Oct;30(10):475-87. doi: 10.1016/j.it.2009.07.009. Epub 2009 Sep 24.
8
Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences.内毒素耐受的病理生理学：机制与临床后果
Crit Care. 2013 Nov 14;17(6):242. doi: 10.1186/cc13110.
9
PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α.PD-L1 在外毒素耐受期间的过表达通过 HIF1α 损害脓毒症患者的适应性免疫反应。
J Infect Dis. 2018 Jan 17;217(3):393-404. doi: 10.1093/infdis/jix279.
10
Mitochondrial Sirtuin 4 Resolves Immune Tolerance in Monocytes by Rebalancing Glycolysis and Glucose Oxidation Homeostasis.线粒体 Sirtuin 4 通过重新平衡糖酵解和葡萄糖氧化稳态来解决单核细胞中的免疫耐受。
Front Immunol. 2018 Mar 9;9:419. doi: 10.3389/fimmu.2018.00419. eCollection 2018.
引用本文的文献
1
Energetic dysfunction in sepsis: a narrative review.脓毒症中的能量代谢功能障碍：一项叙述性综述
Ann Intensive Care. 2021 Jul 3;11(1):104. doi: 10.1186/s13613-021-00893-7.
2
Metabolic substrate utilization in stress-induced immune cells.应激诱导免疫细胞中的代谢底物利用
Intensive Care Med Exp. 2020 Dec 18;8(Suppl 1):28. doi: 10.1186/s40635-020-00316-0.
3
Monocyte Transmodulation: The Next Novel Therapeutic Approach in Overcoming Ischemic Stroke?单核细胞转调：克服缺血性中风的下一种新型治疗方法？
Front Neurol. 2020 Oct 22;11:578003. doi: 10.3389/fneur.2020.578003. eCollection 2020.
4
Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19.COVID-19 超高炎症反应中循环细胞因子与白细胞自发性细胞因子产生之间的不匹配。
J Leukoc Biol. 2021 Jan;109(1):115-120. doi: 10.1002/JLB.5COVBCR0720-310RR. Epub 2020 Aug 13.
本文引用的文献
1
Sepsis Induces a Long-Lasting State of Trained Immunity in Bone Marrow Monocytes.脓毒症诱导骨髓单核细胞产生持久的训练免疫状态。
Front Immunol. 2018 Nov 19;9:2685. doi: 10.3389/fimmu.2018.02685. eCollection 2018.
2
Late mortality after sepsis: propensity matched cohort study.脓毒症后的晚期死亡率：倾向匹配队列研究
BMJ. 2016 May 17;353:i2375. doi: 10.1136/bmj.i2375.
3
Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.脓毒症中的免疫抑制与继发感染：只是部分而非全部情况
JAMA. 2016 Apr 12;315(14):1457-9. doi: 10.1001/jama.2016.2762.
4
Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.评估全球医院治疗脓毒症的发病率和死亡率。当前的估计和局限性。
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. doi: 10.1164/rccm.201504-0781OC.
5
Why have clinical trials in sepsis failed?为什么脓毒症临床试验会失败？
Trends Mol Med. 2014 Apr;20(4):195-203. doi: 10.1016/j.molmed.2014.01.007. Epub 2014 Feb 24.
6
Epidemiology of severe sepsis.严重脓毒症的流行病学。
Virulence. 2014 Jan 1;5(1):4-11. doi: 10.4161/viru.27372. Epub 2013 Dec 11.
7
The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?脓毒症中不断变化的免疫系统：个体化免疫调节治疗是答案吗？
Virulence. 2014 Jan 1;5(1):45-56. doi: 10.4161/viru.26516. Epub 2013 Sep 25.
8
The search for effective therapy for sepsis: back to the drawing board?寻找脓毒症的有效治疗方法：要从头开始吗？
JAMA. 2011 Dec 21;306(23):2614-5. doi: 10.1001/jama.2011.1853.
Zotero 插件